BioMedNewsBreaks Archive - Page 20 of 250

ThursdayAug 28, 2025 9:00 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Integrates Proprietary AI Algorithm into Breast CT Imaging System

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for breast cancer care, announced the integration of its proprietary AI-based machine-learning reconstruction algorithm into its flagship IzoView Breast CT Imaging System. Developed in collaboration with The Johns Hopkins University School of Medicine, the algorithm is designed to improve image quality while maintaining low radiation doses. Unlike conventional denoising methods such as Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR), which are limited by speed and workflow practicality, Izotropic’s approach addresses image noise at its source, offering a potential breakthrough for clinical efficiency in breast…

WednesdayAug 27, 2025 11:19 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced its expanded access policy for NRX-100 (preservative-free ketamine) after receiving FDA Fast Track designation for the treatment of suicidal ideation in patients with depression, including bipolar depression. The designation reflects FDA’s determination that NRX-100 may address an unmet need based on preliminary data. Eligible patients may access the investigational therapy under specific conditions, including lack of response or tolerance to approved treatments and sufficient supporting clinical data. Chairman and CEO Dr. Jonathan C. Javitt said the company is committed to making NRX-100 available to patients with suicidal depression who have limited…

WednesdayAug 27, 2025 10:49 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in novel treatments for primary and metastatic brain cancers, was featured in the latest episode of The BioMedWire Podcast hosted by IBN. CEO John Climaco detailed the company’s mission to address the urgent unmet need in glioblastoma, its seamless transition from the berubicin trial to advancing the TPI 287 program, and the broader market opportunities in aggressive cancers such as triple-negative breast cancer with brain metastases. Climaco underscored CNS Pharmaceuticals’ operational expertise, commitment to accelerating development, and vision to bring hope to patients facing limited treatment options. To view the full press…

TuesdayAug 26, 2025 3:10 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care

HeartBeam (NASDAQ: BEAT) has secured foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system. “The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings,” reads a recent article. “With the clearance secured, HeartBeam plans to expand access through early access programs, deploy field-testing among medical practices and ultimately commercialize the system. The anticipated sequence of steps includes physician training, system support and data collection to streamline regulatory and commercial readiness. With a transformative…

TuesdayAug 26, 2025 11:10 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Partners With LUNR Aerospace to Advance AI-Driven Space Medicine

Fifty 1 Labs (OTC: FITY) announced that its subsidiary, Fifty 1 AI Labs, has entered into a partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives for space medicine. The collaboration will address key health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection, cardiovascular stability, cognitive performance, sleep optimization and metabolic longevity. Pilot programs will test AI-curated therapeutics and nutraceuticals in space-relevant conditions, offering a cost-efficient path to innovation. With the global space medicine market projected to grow from USD 948.7 million in 2025 to USD 1.97 billion by 2032 at an 11% CAGR, the partnership positions…

TuesdayAug 26, 2025 10:10 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Healthcare Operations With New Leadership and Investments

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels, announced a strategic expansion of its healthcare operations. The initiative includes new senior leadership appointments and investments aimed at supporting growth into high-value patient services. To view the full press release, visit: https://ibn.fm/Kbuab About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and…

TuesdayAug 26, 2025 9:30 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Announces $300K Private Placement and Warrant Extension

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on imaging-based products for breast cancer care, announced plans for a non-brokered private placement of up to 1.2 million units at $0.25 each to raise gross proceeds of up to $300,000. Each unit will include one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. The Company also extended the expiry of 2,841,325 warrants issued in September 2023 by one year to September 20, 2026, with all other terms unchanged. The warrant extension remains subject to final…

FridayAug 22, 2025 9:00 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to distal sites of disease, announced the closing of its underwritten public offering and the full exercise of the underwriters’ over-allotment option for gross proceeds of $6.9 million before deducting commissions and expenses. The Company sold 1,922,764 common stock units, each consisting of one share and one Series I warrant, and 1,528,000 pre-funded warrant units, each consisting of one pre-funded warrant and one Series I warrant. The offering included 450,000 common stock units purchased under the over-allotment option. Common Stock Units were priced at…

ThursdayAug 21, 2025 1:00 pm

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) IP Momentum Continues with New Patents Advancing 3D ECG Technology

HeartBeam (NASDAQ: BEAT) recently secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology. Focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, the company now holds more than 20 U.S. and international patents, with additional applications pending. “HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility,” said HeartBeam CEO Robert Eno. “The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our…

WednesdayAug 20, 2025 3:03 pm

BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM)

BioAdaptives (OTCMKTS: BDPT), a developer of natural health and performance supplements, said its nootropic formula MyndMed(TM) was certified clean by TruShield(TM) Laboratory Services following testing for World Anti-Doping Agency compliance. TruShield, whose protocols are trusted by professional sports organizations including the UFC(R), confirmed MyndMed contains no banned substances and meets safety standards for competitive athletes. BioAdaptives said the clearance supports integration of MyndMed into the UFC’s approved supplement pool, providing fighters with cognitive performance, focus and reaction-time support without risk of anti-doping violations. To view the full press release, visit https://ibn.fm/4b4Xj About BioAdaptives, Inc. BioAdaptives, Inc. develops and markets science-based…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Integrates Proprietary AI Algorithm into Breast CT Imaging System

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Partners With LUNR Aerospace to Advance AI-Driven Space Medicine

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Healthcare Operations With New Leadership and Investments

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Announces $300K Private Placement and Warrant Extension

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) IP Momentum Continues with New Patents Advancing 3D ECG Technology

BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM)

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search